ClinicalTrials.gg
CompletedNCT06582589HEALSPICUpdated Jul 22, 2025

HEALSea Nasal Spray for Prevention of Infections in Children

A Phase 2/3 interventional study of Healsea Children in Healthy Subjects, sponsored by Lallemand Pharma AG. Completed at 8 sites in Bulgaria. Open to participants aged 6 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Lallemand Pharma AG · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Respiratory Tract Infections with a site in Bulgaria — 2 open to participants now, 2 under way, 2 of them phase 3. Respiratory Tract Infections · Bulgaria.

Enrollment
8th of 12
139 · median 199
Started
2024
with 2 others
Phase 2/3
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
3 of 12
Lallemand Pharma AG

Among the 12 studies in Respiratory Tract Infections with a site in Bulgaria, this one is the 8th largest by enrollment, is one of 3 that started in 2024, is the only one in phase 2/3, and was the 10th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 12 studies in Respiratory Tract Infections with a site in Bulgaria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Respiratory Tract Infections with a site in Bulgaria, or all of them as a file.
02

Study summary

Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds.

Symbiofilm™, which is not a medicinal product is able to protect the nasal mucosa from viruses' entrance by forming a protective barrier on the nasal mucosa.

By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections such as cold or flu with nasal symptoms.

The main objective of this premarket clinical investigation is thus to assess the efficacy of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.

138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.

The subjects (or their parents) will be asked to report the upper respiratory tract infections with nasal symptoms and complication they may have during the study to the physician in charge of the study conduct.

Two study visits and 3 telephone calls are scheduled. The subjects will also complete an electronic diary to report nasal symptoms and adverse event other than upper respiratory tracts infections.

Read the detailed description

Upper respiratory tract infections (URTIs) and sino-nasal symptoms are very frequent.

Human rhinovirus (more than 100 serotypes) is the most common cause, accounting up to 50% viral rhinitis episodes in children and adults. These episodes can last up to 7-10 days and are usually self-limited. Prevalence of acute rhinosinusitis varies with season (higher in the fall and winter months) and climatic variations and increases with a damp environment and air pollution. It is estimated that an infant can typically have up to 11 upper respiratory tract infection episodes per year with URTIs being one of the main causes of primary care consultations. The number usually diminishes with age, with generally around eight episodes at preschool age and four at school age.

Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds and rhinitis. The clinical performance of Healsea® Children is supported by the sea water solution and Symbiofilm™. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleaning of the nasal mucosa.

The other component of Healsea® Children, Symbiofilm™ is an exopolymeric composition with emulsifying/surfactant properties which enhance the cleansing and moistening of nasal mucosa. Furthermore, a prophylactic activity of Symbiofilm™ against infection by viruses involved in upper respiratory infections i.e., Adenovirus, Rhinovirus, Flu virus and OC 43 Coronavirus has been demonstrated in vitro on human nasal epithelial cells (HNEpC). The antiviral prophylactic activity of Symbiofilm™ is suggested to rely on its physiochemical properties that, by coating the surface of epithelial cells, hinders the viral entry process, thus explaining the reduced viral adsorption and the subsequent reduced onset of infection.

By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections with nasal symptoms.

The aim of this two arms prospective randomized open-labelled pre-market clinical investigation, is to establish clinical benefits and clinical safety of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days (one puff in each ostril twice daily) interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.

138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.

The subjects (or their parents) will be asked to immediately call the investigator in case of nasal symptoms and complication of respiratory infection they may have during the study.

Two study visits (Visit 1, Screening/Randomisation at Day 1 and Visit 2, End of study visit at Day 106 up to Day 116) and 3 telephone calls (telephone call 1 TC1 at Day15 ±3 days, TC2 at Day 55 ±3 days and TC3 at Day 95±3days) are scheduled. The subjects will also complete an electronic diary to report nasal symptoms, device deficiencies, and adverse events other than upper respiratory tracts infections from D2 up to end of study (Day 106 up to Day 116).

The duration of patient's participation is up to 116 days.

03

Conditions studied

  • Healthy Subjects

Keywords

  • Prevention
  • Nasal spray
  • upper respiratory tract infection
  • saline solution
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/Female subjects ≥6 and \<18-year-old
  2. No respiratory tract infection within 15 days before trial entry and at trial entry
  3. Written consent obtained from parent/legal guardians
  4. Written assent obtained from patient
  5. Availability of a smartphone throughout the study and an internet connection.-

Exclusion criteria

Exclusion Criteria:

  1. Known /allergy to any component of the test device,
  2. Subject with severe asthma, perennial allergy, cystic fibrosis, immunodeficiency or ciliary dyskinesis,
  3. Body temperature ≥ 37.5°
  4. Medical history or any current disease that is considered by the investigator as a reason for non-inclusion,
  5. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps,
  6. Antibiotic (systemic or per nasal route) or antivirals (systemic) intake within 2 weeks before screening,
  7. Systemic or local (nasal route or inhalation) within 4 weeks before screening,
  8. Antihistamines intake for allergy when treatment was started from less than 4 weeks before screening,
  9. Vaccination against flu or COVID-19 within 6 months before screening,
  10. Chronic decongestant use within 2 weeks before screening,
  11. Bacterial lysates or immunostimulants (food supplements excluded) used for prevention of infection within the 6 months before the screening,
  12. Prebiotics, probiotics used for prevention of infection within 6 months before the screening,
  13. Pregnant/Lactating female or with sexual activity without hormonal , intrauterine device or barrier methods.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Healsea Children treated group

    Subjects of this arm will be treated with Healsea Children nasal spray (1 puff in each nostril twice daily) during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days

    Device: Healsea Children

  • No intervention
    untreated group

    Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection.

Interventions

  • DeviceHealsea Children

    Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out

06

What researchers measure

Primary outcomes

  1. Proportion of subjects without any upper respiratory tract infection (URTI) with nasal symptoms during the study.

    The upper respiratory tracts infections with nasal symptoms (blocked nose, runny nose yellow or green discharge, sneezing ) will be collected for each subject throughout An URTI episode with nasal symptoms is defined as follows: (i) at least 1 of the followings must be present: a blocked nose, runny nose, yellow or green nasal discharge, sneezing; (ii) the symptomatic episode must last for at least 3 days.

    Time frame: From the randomization up to Day 116

Secondary outcomes

  1. Time to first Upper Respiratory Tract Infection with nasal symptoms during the study

    The time to first Upper Respiratory Tract Infection with nasal symptoms (blocked nose, runny nose, yellow or green discharge, sneezing) will be compared between groups

    Time frame: From the randomization up to Day 116

  2. Number of Upper Respiratory Tract Infections with nasal symptoms during the study

    Upper Respiratory Tract Infections with nasal symptoms will be reported by the subjects to the investigators during the whole study duration and the total number compared between groups

    Time frame: From the randomization up to Day 116

  3. Number of Upper Respiratory Tract Infections complications

    Complications of Upper respiratory Tract Infections (bronchitis, bronchiolitis, pneumoniae, pharyngo-tonsillitis, laryngitis, acute otitis) will be reported by the subjects during the whole study duration and compared between groups

    Time frame: From the randomization up to Day 116

  4. Number of days of use of concomitant treatments that may affect Upper Respiratory Tract Infections symptoms and associated complications

    The number of days of antipyretics intake, systemic or local mucolytics, decongestants, antitussives, systemic and per nasal route antibiotics, local and systemic corticosteroids, systemic antivirals) will be compared between the 2 arms

    Time frame: From the randomization up to Day 116

  5. Number of school days lost due to Upper Respiratory Tract Infections and complications

    Number of school days lost due to Upper Respiratory Tract Infections and complications will be collected during the whole study duration and compared between groups

    Time frame: From the randomization up to Day 116

  6. Assessment of (serious) adverse events and device deficiences throughout the study

    Time frame: From the randomization up to Day 116

07

Study locations

8 sites
  • Multiprofile Hospital for Active Treatment Sveti Ivan Rilski -2003 OOD
    Dupnitsa, 2600, Bulgaria
  • Medical Center Plovdimed Ltd
    Plovdiv, 4023, Bulgaria
  • Medical Center Iskar EOOD
    Sofia, 1000, Bulgaria
  • Medical Center Polymed AD
    Sofia, 1303, Bulgaria
  • Medical Center First Pediatric
    Sofia, 1404, Bulgaria
  • Multiprofile Hospital for active treatment
    Sofia, 1618, Bulgaria
  • Diagnostics and Consultation Center Convex EOOD
    Sofia, 1680, Bulgaria
  • Ambulatory for individual Practice for specialized outpatient medical care for children&#39;s diseases and pediatric pneumology ans phtysiatry
    Vratsa, 3001, Bulgaria
08

References and documents

Publications

  • Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 2004 Nov;124(9):1059-62. doi: 10.1080/00016480410017657. PubMed 15513550 ↗
  • Cabaillot A, Vorilhon P, Roca M, Boussageon R, Eschalier B, Pereirad B. Saline nasal irrigation for acute upper respiratory tract infections in infants and children: A systematic review and meta-analysis. Paediatr Respir Rev. 2020 Nov;36:151-158. doi: 10.1016/j.prrv.2019.11.003. Epub 2020 Feb 21. PubMed 32312677 ↗
  • Stanfel D, Kalogjera L, Ryazantsev SV, Hlaca K, Radtsig EY, Teimuraz R, Hrabac P. The Role of Seawater and Saline Solutions in Treatment of Upper Respiratory Conditions. Mar Drugs. 2022 May 17;20(5):330. doi: 10.3390/md20050330. PubMed 35621981 ↗
  • Slapak I, Skoupa J, Strnad P, Hornik P. Efficacy of isotonic nasal wash (seawater) in the treatment and prevention of rhinitis in children. Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):67-74. doi: 10.1001/archoto.2007.19. PubMed 18209140 ↗
  • Williamson S, Dennison L, Greenwell K, Denison-Day J, Mowbray F, Richards-Hall S, Smith D, Bradbury K, Ainsworth B, Little P, Geraghty AWA, Yardley L. Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews. BMJ Open. 2022 Jun 30;12(6):e059661. doi: 10.1136/bmjopen-2021-059661. PubMed 35772824 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Apr 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Nov 25, 2024
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582589
Lead sponsor
Lallemand Pharma AG
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Nov 25, 2024
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Last update
Jul 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion